# OnCo record nct05862272 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05862272/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05862272", "NCT05862272" ;
  schema:name "A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis"@en ;
  schema:description "A phase 3 trial of Relugolix in endometrial cancer, run by Sumitomo Pharma Switzerland GmbH, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05862272/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05862272> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-08-14" ;
  onco:cancers <https://onco.cc/cancers/endometrial/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:drugs <https://onco.cc/drugs/relugolix/> ;
  onco:companies <https://onco.cc/companies/sumitomo-pharma/> .